At the 2024 UCSF-UCLA PSMA Conference, Jeremie Calais discusses the critical role of PSMA PET in selecting patients for PSMA radiopharmaceutical therapy, using the VISION trial criteria to highlight the importance of precise patient selection based on PSMA PET imaging for predicting treatment effectiveness and side effects.
|